Healthcare Equipment and Supplies
Company Overview of Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc. provides in vitro diagnostics solutions to clinical laboratories and immunohematology communities worldwide. It offers chemistry and immunodiagnostics solutions, which include integrated chemistry systems, chemistry systems, immunodiagnostic systems, laboratory automation and middleware solutions, and acute kidney injury-acute renal failure testing devices and meters; and transfusion medicine solutions, including immunohematology analyzers, workstations, and reagents, as well as donor screening solutions. The company also provides predictive technologies, inventory management, laboratory optimization, and training and education services. Its portfolio of prod...
1001 US 202
Raritan, NJ 08869
Founded in 1974
Key Executives for Ortho-Clinical Diagnostics, Inc.
Chairman and Chief Executive Officer
Chief Operating Officer and Executive Vice President
Executive Vice President and General Counsel
Executive Vice President of Commercial Operations
Compensation as of Fiscal Year 2017.
Ortho-Clinical Diagnostics, Inc. Key Developments
Ortho-Clinical Diagnostics Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-09-2018 10:30 AM
Jan 5 18
Ortho-Clinical Diagnostics Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-09-2018 10:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.
Ortho Clinical Diagnostics Announces the Launch of VITROS® ALTV Slides
Dec 19 17
Ortho Clinical Diagnostics announced the launch of VITROS® ALTV Slides, a new and novel method for the measurement of alanine aminotransferase (ALT), a key liver function enzyme found in serum and plasma, utilizing dry slide technology. ALT is used in the diagnosis and treatment of certain liver diseases (e.g., viral hepatitis and cirrhosis) as well as heart diseases. Due to its distribution primarily in the liver, elevated ALT levels are highly suggestive of liver damage, and ALT measurements are particularly useful in the diagnosis and management of liver disease. Because it is available using dry slide technology, VITROS ALTV Slides confers several operational and clinical advantages for the clinical laboratory and physicians, including low patient sample volumes needed for testing, extended calibration stability and minimal storage space requirements, along with excellent precision performance and low-end sensitivity. Dry slide technology is unique in that it does not require water, plumbing and drains, or the need to dispose of water as medical waste. It also eliminates the need for high quality water as a requirement for testing. This "waterless" environment makes dry slide technology ideal for a broad array of testing environments.
Ortho-Clinical Diagnostics, Inc. Receives U.S. Food and Drug Administration Approval for Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator on the Vitros® 3600 Immunodiagnostic System
Dec 18 17
Ortho Clinical Diagnostics announced that its VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (VITROS® HIV Combo test) received approval from the U.S. Food and Drug Administration for use on Ortho's VITROS 3600 Immunodiagnostic Systemi. VITROS HIV Combo, a fourth-generation test, detects both HIV-1 and HIV-2 antibodies (Ab) and the p24 antigen (Ag), enabling HIV-1 acute infection detection earlier than third-generation testsii. The clinical and technical performance of the VITROS HIV Combo test on VITROS® Systems was evaluated during routine use at three external testing laboratories in the US and at Ortho's research and development laboratories. This assessment confirmed that the test provides competitive sensitivity and specificity when compared to a leading commercially available fourth-generation test[i]v. In the comparison studiesiv, assay sensitivity was evaluated on seroconversion panels. The VITROS HIV Combo test showed earlier detection of acute HIV infection in six of 32 seroconversion panels (agreement for 25 of 32 panels) when compared to a leading commercially available fourth-generation Ag/Ab test, indicating that the assay performance is very competitive in shortening the diagnostic window (the time between HIV infection and detection) - a valuable attribute in HIV testing. The test's excellent p24 sensitivity with uncompromised specificity is enhanced by a combination of proprietary technologies and benefits only available on VITROS Systems: MicroWell technology combined with Enhanced Chemiluminescence Detection Technology improves signal, detection with outstanding sensitivity precision and a wide dynamic range. The Intellicheck® Technology with its suite of quality checks, including MicroSensor technology detects endogenous interferences; SMART Metering and VersaTip technology which helps exclude carryover and cross-contamination using disposable tips. These provide laboratories the accuracy needed to have the utmost trust in their results.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|